2
项与 西妥昔单抗生物类似药(EnZene Biosciences) 相关的临床试验A prospective, multicenter, Phase IV study to evaluate the safety and efficacy of biosimilar cetuximab either alone or in combination with investigator choice chemotherapy/ radiotherapy in patients with locoregionally advanced or recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN). - NIL
/ Active, not recruiting临床3期 A prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination withplatinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN).
100 项与 西妥昔单抗生物类似药(EnZene Biosciences) 相关的临床结果
100 项与 西妥昔单抗生物类似药(EnZene Biosciences) 相关的转化医学
100 项与 西妥昔单抗生物类似药(EnZene Biosciences) 相关的专利(医药)
100 项与 西妥昔单抗生物类似药(EnZene Biosciences) 相关的药物交易